AU2004234003A1 - Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug - Google Patents

Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug Download PDF

Info

Publication number
AU2004234003A1
AU2004234003A1 AU2004234003A AU2004234003A AU2004234003A1 AU 2004234003 A1 AU2004234003 A1 AU 2004234003A1 AU 2004234003 A AU2004234003 A AU 2004234003A AU 2004234003 A AU2004234003 A AU 2004234003A AU 2004234003 A1 AU2004234003 A1 AU 2004234003A1
Authority
AU
Australia
Prior art keywords
composition
agent
surfactant
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004234003A
Other languages
English (en)
Inventor
Mark J. Doty
James E. Kipp
Pavlos Papadopoulos
Barrett E. Rabinow
Christine L. Rebbeck
Chong-Son Sun
Randy White
Joseph Chung Tak Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of AU2004234003A1 publication Critical patent/AU2004234003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2004234003A 2003-04-29 2004-04-29 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug Abandoned AU2004234003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46635403P 2003-04-29 2003-04-29
US60/466,354 2003-04-29
PCT/US2004/013268 WO2004096180A1 (fr) 2003-04-29 2004-04-29 Formulation destinee a rendre un medicament antimicrobien efficace contre des organismes normalement consideres comme etant resistant a ce medicament

Publications (1)

Publication Number Publication Date
AU2004234003A1 true AU2004234003A1 (en) 2004-11-11

Family

ID=33418369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004234003A Abandoned AU2004234003A1 (en) 2003-04-29 2004-04-29 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

Country Status (11)

Country Link
EP (1) EP1617818A1 (fr)
JP (1) JP2006525345A (fr)
KR (1) KR20060015553A (fr)
CN (1) CN1794975A (fr)
AU (1) AU2004234003A1 (fr)
BR (1) BRPI0409929A (fr)
CA (1) CA2523151A1 (fr)
MX (1) MXPA05011607A (fr)
NO (1) NO20055616L (fr)
WO (1) WO2004096180A1 (fr)
ZA (1) ZA200508467B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100858508B1 (ko) 2005-12-23 2008-09-12 주식회사 삼양사 아졸계 항진균제를 포함하는 조성물 및 그의 제조방법
BRPI0712130A2 (pt) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
LT2722053T (lt) * 2010-12-30 2017-12-11 Aktsionernoye Obshchestvo "Nauchnyi Tsentr Protivoinfektsionnyh Preparatov" Antibakterinis agentas, skirtas bakterinės kilmės infekcinių ligų gydymui
CN102085176A (zh) * 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
CN102106832A (zh) * 2011-02-12 2011-06-29 华中师范大学 酮康唑纳米混悬剂冻干粉及其制备方法
EP3319608A4 (fr) * 2015-07-07 2019-04-03 LifeRaft Biosciences, Inc. Formulations de poloxamère-188 à teneur en sodium réduite et procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69914742T2 (de) * 1998-05-29 2004-11-25 Skyepharma Canada Inc., Verdun Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
DE60020382T2 (de) * 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
CN100512798C (zh) * 2000-12-22 2009-07-15 巴克斯特国际公司 亚微米颗粒悬浮液制备方法
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix

Also Published As

Publication number Publication date
WO2004096180A1 (fr) 2004-11-11
NO20055616L (no) 2006-01-25
CN1794975A (zh) 2006-06-28
NO20055616D0 (no) 2005-11-28
CA2523151A1 (fr) 2004-11-11
KR20060015553A (ko) 2006-02-17
JP2006525345A (ja) 2006-11-09
EP1617818A1 (fr) 2006-01-25
MXPA05011607A (es) 2005-12-15
ZA200508467B (en) 2006-09-27
BRPI0409929A (pt) 2006-04-25

Similar Documents

Publication Publication Date Title
US8263131B2 (en) Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug
US20030072807A1 (en) Solid particulate antifungal compositions for pharmaceutical use
AU2002337894B2 (en) Stable composition comprising particles in a frozen aqueous matrix
US9044381B2 (en) Method for delivering drugs to the brain
US20050244503A1 (en) Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
US20050202094A1 (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
ZA200508467B (en) Formulation to render an antimicrobial drug potentagainst organisms normally considered to be resistant to the drug
US20060280786A1 (en) Pharmaceutical formulations for minimizing drug-drug interactions
MXPA06008533A (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application